Page 2 - ேசை மூலோபாய இணைந்து News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ேசை மூலோபாய இணைந்து. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ேசை மூலோபாய இணைந்து Today - Breaking & Trending Today

Fierce Pharma Asia—Takeda's CMV drug win; Merck and Eisai's kidney cancer showing; Botox rival Jeuveau's settlement

Merck and Eisai showed their Keytruda-Lenvima combo could cut the risk of death by 34% over Pfizer’s old standard treatment Sutent in newly diagnosed kidney cancer. While the overall survival showing was very similar to the numbers for three other immuno-oncology cocktails based on Keytruda or Bristol Myers Squibb’s Opdivo, SVB Leerink analyst Daina Graybosch pointed to other efficacy data in crowning the Keytruda-Lenvima pairing as the “clear choice.” But the win is not a done deal at this point, she noted.
AbbVie’s Allergan and its South Korean partner MedyTox have decided to settle the legal battle they waged against Evolus and its own Korean partner Daewoong Pharmaceutical over their wrinkle-lifting drugs. The news came on the heels of a U.S. appeals court s decision to temporarily allow the Evolus pair’s Botox rival, Jeuveau, to stay on the U.S. market as it reviewed an import ban installed by the U.S. International Trade Commission. AbbVie and Medytox aba ....

United Kingdom , South Korea , South Korean , Abbvie Allergan , Bristol Myers Squibb Opdivo , Daina Graybosch , Daewoong Pharma , Eisai Keytruda Lenvima , Syneos Health , Rare Disease Innovations Institute , Serum Institute Of India , Us International Trade Commission , Rare Disease , Making Progress , Gene Therapies , Webinar Series , Bristol Myers Squibb , Daewoong Pharmaceutical , Serum Institute , Merck Amp Co , Pd 1 L1 , Kidney Cancer , Trade Secrets , Covid 19 , Vaccine Manufacturing , Plant Inspections ,

Eisai to Launch Parkinson's Disease Treatment Equfina in South Korea

Eisai to Launch Parkinson s Disease Treatment Equfina in South Korea
TOKYO, Feb 1, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that Eisai Korea Inc., Eisai s subsidiary in South Korea, has launched the Parkinson s disease treatment Equfina (safinamide mesilate, safinamide ). This is the first launch of Equfina in the Asian region excluding Japan.
The estimated number of patients with Parkinson s disease is approximately 150,000 in South Korea. Parkinson s disease has high unmet medical needs because of inadequate symptom control using current medications, necessitating new treatment options. This disease is designated as a rare intractable disease in South Korea.
The marketing approval of this drug in South Korea is primarily based on a double-blind, placebo-controlled, Phase III Study (SETTLE study) conducted overseas (including South Korea) to evaluate the efficacy and safety of 24-week oral administration of the once-daily safinamide as an add-on to lev ....

United States , Hong Kong , Republic Of , South Korea , E Ray Dorsey , Japanese Society Of Neurology Parkinson , Newron Pharmaceuticals , Eisai Co Ltd , Public Relations Department , Eisai Korea Inc , Meiji Seika Pharma Co Ltd , Japan Intractable Diseases Information Center , Levodopa Adjunct , Patients With Parkinson Disease , Motor Fluctuations , Randomized Clinical , Global Burden , Disease Study , Japanese Society , Relations Department , ஒன்றுபட்டது மாநிலங்களில் , ஹாங் காங் , குடியரசு ஆஃப் , தெற்கு கொரியா , ஏ ராய் டோர்ஸி , ஜப்பானிய சமூகம் ஆஃப் நரம்பியல் பார்கின்சன் ,

U.S. FDA extends review period for Biogen's Alzheimer's drug to June

Message :
Required fields
(Reuters) - Biogen Inc and partner Eisai Co Ltd said on Friday the U.S. Food and Drug Administration has extended the review period for their experimental Alzheimer s disease treatment by three months from March.
Biogen s shares rose about 10% as the FDA extension raised some hopes that the drug may still be approved despite a panel of experts to the FDA voting against it in November.
Our key takeaway is that if the FDA would have wanted to reject the drug, we would have heard the decision by now, said Truist analyst Robyn Karnauskas.
An FDA approval would make the drug, aducanumab, the first new treatment for Alzheimer s in decades and the first that appears to be able to slow progression of the fatal, mind-wasting condition that affects millions of people. ....

Robyn Karnauskas , Manojna Maddipatla , Christopher Raymond , Manas Mishra , Shounak Dasgupta , Dania Nadeem , Piper Sandler , Anild Silva , Eisai Co , Ltd Stock Exchange , Press Release , Months 4523 Jp3160400002 , கிறிஸ்டோபர் ரேமஂட் , மனஸ் மிஸ்ரா , ஷ்ௌுனாக் தாஸ்குப்தா , டானியா நதீம் , பைபர் சாண்ட்லர் , ேசை இணை , லிமிடெட் ஸ்டாக் பரிமாற்றம் , ப்ரெஸ் வெளியீடு ,

Eisai to Present Abstracts on Lenvatinib at 2021 Gastrointestinal Cancers Symposium

Eisai to Present Abstracts on Lenvatinib at 2021 Gastrointestinal Cancers Symposium
TOKYO, Jan 12, 2021 - (JCN Newswire) - Eisai Co., Ltd. has announced that presentations on a series of abstracts highlighting updates on its in-house discovered lenvatinib mesylate (product name: LENVIMA, the orally available kinase inhibitor, lenvatinib ) will be given at the Gastrointestinal Cancers Symposium Virtual Meeting, from January 15 to 17, 2021.
At this symposium, regarding the lenvatinib monotherapy, the real-world effectiveness among unresectable hepatocellular carcinoma (HCC) patients treated in United States clinical practices (Abstract No: 273), as well as the results of a post hoc analysis of patients with unresectable HCC who progressed to the Child-Pugh B stage in the Phase 3 REFLECT study (Abstract No: 298), will be presented. ....

United States , Merck Co Inc , Eisai Co Ltd , Public Relations Department , United Statesa , Eisai Strategic , Relations Department , ஒன்றுபட்டது மாநிலங்களில் , மெர்க் இணை இன்க் , ேசை இணை லிமிடெட் , பொது உறவுகள் துறை , ேசை மூலோபாய , உறவுகள் துறை , இரைப்பை குடல் ,